xers-20210503

0001346302-21-000040.txt : 20210506 0001346302-21-000040.hdr.sgml : 20210506 20210506160400 ACCESSION NUMBER: 0001346302-21-000040 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210503 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 21897635 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 8-K 1 xers-20210503.htm 8-K xers-20210503

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2021 (May 3, 2021)

XERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38536

20-3352427

(State or other jurisdiction of
incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

180 N. LaSalle Street, Suite 1600

Chicago, Illinois 60601

(Address of principal executive offices, including zip code)

(844) 445-5704

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

XERS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

Fifth Amendment to Amended and Restated Loan and Security Agreement

On May 3, 2021, the Company entered into a Fifth Amendment to Amended and Restated Loan and Security Agreement (the “Fifth Amendment”) with Oxford Finance LLC, as the collateral agent and a lender (“Oxford”), and Silicon Valley Bank, as a lender (“SVB”, and together with Oxford, the “Lenders”) to amend that certain Amended and Restated Loan and Security Agreement, dated as of September 10, 2019, by and between the Company and the Lenders (as amended, supplemented or otherwise modified from time to time, including by that certain First Amendment to Amended and Restated Loan and Security Agreement dated as of April 21, 2020, that certain Second Amendment to Amended and Restated Loan and Security Agreement dated June 30, 2020, that certain Third Amendment to Amended and Restated Loan and Security Agreement dated August 5, 2020, and that certain Fourth Amendment to Amended and Restated Loan and Security Agreement dated October 23, 2020, collectively, the “Amended and Restated Loan and Security Agreement”).

The Fifth Amendment allows for the interest-only payment period applicable to the term loans outstanding under the Amended and Restated Loan and Security Agreement (the “Term Loans”), previously payable in 30 equal monthly installments beginning January 1, 2022, to be extended. If the Company achieves a certain revenue milestone prior to November 30, 2021, then the period for interest-only payments is extended to July 1, 2022 and the Term Loans will be payable in 24 equal monthly installments. In addition, if the Company achieves an additional certain revenue milestone prior to May 31, 2022, the period for interest-only payments is further extended to October 1, 2022 and the Term Loans will be payable in 21 equal monthly installments. Finally, if the Company achieves an additional certain revenue milestone prior to August 31, 2022, then the period for interest-only payments is further extended to January 1, 2023, and the Term Loans will be payable in 18 equal monthly installments.

Pursuant to the Fifth Amendment, the Company is required to pay a non-refundable amendment fee in the amount of $35,000 at the earliest to occur of (i) the maturity date, (ii) the acceleration of any Term Loan and (iii) the prepayment of any Term Loan amount.

The foregoing description of the Fifth Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2021.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:


Exhibit Number						Description
99.1						Press release issued by Xeris Pharmaceuticals, Inc. dated May 3, 2021
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 6, 2021	Xeris Pharmaceuticals, Inc.

	By:	/s/ Barry M. Deutsch
		Barry M. Deutsch
		Chief Financial Officer

EX-99.1 2 expandedsvboxforddebtmay20.htm EX-99.1 Document

Exhibit 99.1

XERIS PHARMACEUTICALS ANNOUNCES EXTENSION OF THE INTEREST-ONLY PERIOD OF ITS DEBT FACILITY WITH OXFORD FINANCE AND SILICON VALLEY BANK

Provides up to 12 months of interest-only payments to January 2023 upon achievement of certain revenue targets

Delays up to $17.4 million of principal payments

CHICAGO, IL; May 6, 2021 – Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an amendment to its existing loan and security agreement with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB). The amendment allows for extensions of interest-only payments for up to 12 months, subject to certain conditions, to January 2023. The extensions allow the Company to delay principal payments of up to $17.4 million, which would have been due during the periods between January 1, 2022 and December 1, 2022, to periods beginning January 1, 2023. The final maturity date of the debt facility is June 1, 2024.

“Extending the interest-only period for up to one year to January 2023 provides us flexibility from a cash runway perspective, while we continue to build on the momentum of Gvoke and leverage our novel technologies,” said Paul R. Edick, Chairman and CEO of Xeris. “Oxford and SVB have been excellent partners of Xeris over the years supporting our growth as we have transitioned from a development company to a commercial organization.”

“Oxford is pleased to provide Xeris with more flexible repayment terms under the existing credit facility in order to conserve the Company’s cash as it continues to advance its development pipeline and grow sales of Gvoke for the treatment of hypoglycemia,” said Christopher Herr, Senior Managing Director at Oxford.

Under the new terms of the debt facility, of which $43.5 million has been drawn, Xeris is eligible for a 6-month interest-only extension to July 2022, an additional 3-month interest-only extension to October 2022, and another 3-month interest-only extension to January 2023, each upon achievement of certain trailing 6-month revenue targets.

About Xeris Pharmaceuticals, Inc.

Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first U.S. commercial product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn, or Instagram.

About Oxford Finance LLC Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $6 billion in loans, with lines of credit ranging from $5 million to $150 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in San Diego, California, Palo Alto, California, and the greater Boston and New York City areas. For more information, visit oxfordfinance.com.

About Silicon Valley Bank For more than 35 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international, and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Xeris Pharmaceuticals, Inc., including statements concerning plans, projections and estimates regarding the use of proceeds from the credit facility, and other statements containing the words "will," "would," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, without limitation, the regulatory approval of the Company’s product candidates, its ability to fund its operations, capital expenditures, and planned drug development and commercialization efforts, its ability to market and sell its current and future products, if approved, and other factors discussed in the "Risk Factors" section of the most recently filed Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Xeris’ subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Xeris expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

312-736-1237

EX-101.SCH 3 xers-20210503.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 xers-20210503_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 xers-20210503_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 xers-20210503_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, State or Province Entity Address, State or Province Document Information, Document [Axis] Document Information, Document [Axis] Entity Tax Identification Number Entity Tax Identification Number Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Soliciting Material Soliciting Material City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Cover [Abstract] Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Document Type Document Type Entity Registrant Name Entity Registrant Name Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Document [Domain] Document [Domain] Security Exchange Name Security Exchange Name EX-101.PRE 7 xers-20210503_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image_01.jpg begin 644 image_01.jpg MB5!.1PT*&@H -24A$4@ ; "5" 8 Y6*\; 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 9 xers-20210503_htm.xml IDEA: XBRL DOCUMENT 0001346302 2021-05-03 2021-05-03 false 0001346302 8-K 2021-05-03 XERIS PHARMACEUTICALS, INC. DE 001-38536 20-3352427 180 N. LaSalle Street, Suite 1600 Chicago IL 60601 844 445-5704 false false false false Common Stock, par value $0.0001 per share XERS NASDAQ true false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.1

Cover

May 03, 2021

Document Information [Line Items]

Document Type 8-K

Document Period End Date May 03, 2021

Entity Registrant Name XERIS PHARMACEUTICALS, INC.

Entity Incorporation, State or Country Code DE

Entity File Number 001-38536

Entity Tax Identification Number 20-3352427

Entity Address, Address Line One 180 N. LaSalle Street,

Entity Address, Address Line Two Suite 1600

Entity Address, City or Town Chicago

Entity Address, State or Province IL

Entity Address, Postal Zip Code 60601

City Area Code 844

Local Phone Number 445-5704

Written Communications false

Soliciting Material false

Pre-commencement Tender Offer false

Pre-commencement Issuer Tender Offer false

Title of 12(b) Security Common Stock, par value $0.0001 per share

Trading Symbol XERS

Security Exchange Name NASDAQ

Entity Emerging Growth Company true

Entity Ex Transition Period false

Amendment Flag false

Entity Central Index Key 0001346302

Cover	May 03, 2021
Document Information [Line Items]
Document Type	8-K
Document Period End Date	May 03, 2021
Entity Registrant Name	XERIS PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38536
Entity Tax Identification Number	20-3352427
Entity Address, Address Line One	180 N. LaSalle Street,
Entity Address, Address Line Two	Suite 1600
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60601
City Area Code	844
Local Phone Number	445-5704
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	XERS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Amendment Flag	false
Entity Central Index Key	0001346302

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://xerispharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports xers-20210503.htm expandedsvboxforddebtmay20.htm xers-20210503.xsd xers-20210503_cal.xml xers-20210503_def.xml xers-20210503_lab.xml xers-20210503_pre.xml http://xbrl.sec.gov/dei/2021 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "xers-20210503.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "xers-20210503_cal.xml" ] }, "definitionLink": { "local": [ "xers-20210503_def.xml" ] }, "inline": { "local": [ "xers-20210503.htm" ] }, "labelLink": { "local": [ "xers-20210503_lab.xml" ] }, "presentationLink": { "local": [ "xers-20210503_pre.xml" ] }, "schema": { "local": [ "xers-20210503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "xers", "nsuri": "http://xerispharma.com/20210503", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "xers-20210503.htm", "contextRef": "i4a46f5189b8447b587588b9037a11569_D20210503-20210503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://xerispharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "xers-20210503.htm", "contextRef": "i4a46f5189b8447b587588b9037a11569_D20210503-20210503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.", "label": "Document [Domain]", "terseLabel": "Document [Domain]" } } }, "localname": "DocumentDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_DocumentInformationDocumentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Document Information, Document [Axis]", "terseLabel": "Document Information, Document [Axis]" } } }, "localname": "DocumentInformationDocumentAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001346302-21-000040-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001346302-21-000040-xbrl.zip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